- All Drug Categories
- Home
- Anti-cancer Drugs
- Healthcare Products
- Medical Information
- Statement
Targeted management is necessary for joint pain, nausea, and photosensitive reactions that may occur during treatment with Encorafenib. Joint p...
Encorafenib is a targeted drug for BRAFV600E mutant melanoma, exerting anti-tumor effects by inhibiting BRAF kinase activity. The following pro...
Encorafenib is a BRAF inhibitor primarily used to treat melanoma, colorectal cancer, and non-small cell lung cancer with BRAFV600E or V600K mut...
The contraindication population for Conafenib mainly includes BRAF wild-type tumor patients and patients with severe liver function impairment,...
Tucatinib/tocatinib is an oral tyrosine kinase inhibitor targeting HER2 protein, which is particularly suitable for the treatment of HER2 posit...
The common side effects of Tucatinib include nausea, fatigue, and hand foot syndrome, which require targeted management to alleviate symptoms a...
The contraindications for Tucatinib include patients with severe liver injury and QT interval prolongation, and strict adherence to medication ...
Attention should be paid to the risks of diarrhea, hepatotoxicity, and drug interactions when using Tucatinib. Diarrhea may cause severe dehydr...
The administration of Ponatinib should follow the principle of fasting, and dosage adjustments should be graded according to the severity of ad...
Ponatinib has clear contraindications for patients with severe cardiovascular disease and uncontrolled hypertension, and strict risk assessment...
